Comparison of patient report and medical records of comorbidities: Results from a population-based cohort of patients with prostate cancer

JAMA Oncology

Volumn 3, Issue 8, 2017, Pages 1035-1042

  Ye, Fan ^a   Moon, Dominic H ^a   Carpenter, William R ^b,c   Reeve, Bryce B ^b,c   Usinger, Deborah S ^a   Green, Rebecca L ^a   Spearman, Kiayni ^a   Sheets, Nathan C ^a   Pearlstein, Kevin A ^a   Lucero, Angela R ^a   Waddle, Mark R ^a   Godley, Paul A ^b,c   Chen, Ronald C ^a,b,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c University of North Carolina at Chapel Hill   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTHRITIS; ARTICLE; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE EFFECTIVENESS; CORONARY ARTERY DISEASE; EDUCATIONAL STATUS; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; INCOME; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MEDICAL RECORD; PROSTATE CANCER; RACE DIFFERENCE; SELF REPORT; ANCESTRY GROUP; COMPARATIVE STUDY; MIDDLE AGED; NORTH CAROLINA; ODDS RATIO; PREVALENCE; PROSTATIC NEOPLASMS; SOCIOECONOMICS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COMORBIDITY; COMPARATIVE EFFECTIVENESS RESEARCH; CONTINENTAL POPULATION GROUPS; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; NORTH CAROLINA; ODDS RATIO; PREVALENCE; PROSTATIC NEOPLASMS; SELF REPORT; SOCIOECONOMIC FACTORS;

EID: 85029560392     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.6744     Document Type: Article

References (34)

1. Jani AB, Hellman S. Early prostate cancer: clinical decision-making. Lancet. 2003;361(9362):1045-1053.
2. Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol. 2011;29(10):1335-1341.
3. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220-241.
4. American Cancer Society. What are the key statistics about prostate cancer? 2013. http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics. Accessed April 5, 2014.
5. Hall WH, Jani AB, Ryu JK, Narayan S, Vijayakumar S. The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer. Prostate Cancer Prostatic Dis. 2005;8(1):22-30.
6. Lu-Yao GL, Albertsen P, Warren J, Yao SL. Effect of age and surgical approach on complications and short-term mortality after radical prostatectomy: a population-based study. Urology. 1999;54(2): 301-307.
7. Harlan LC, Potosky A, Gilliland FD, et al. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst. 2001;93(24):1864-1871.
8. Desch CE, Penberthy L, Newschaffer CJ, et al. Factors that determine the treatment for local and regional prostate cancer. Med Care. 1996;34(2): 152-162.
9. Yu JB, Soulos PR, Herrin J, et al. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst. 2013;105(1):25-32.
10. Institute of Medicine. IoM: Initial National Priorities for Comparative Effectiveness Research. Washington, DC: National Academies Press; 2009.
11. Reeve BB, Chen RC, Moore DT, et al. Impact of comorbidity on health-related quality of life after prostate cancer treatment: combined analysis of two prospective cohort studies. BJU Int. 2014;114 (6b):E74-E81.
12. Katz JN, Chang LC, Sangha O, Fossel AH, Bates DW. Can comorbidity be measured by questionnaire rather than medical record review? Med Care. 1996;34(1):73-84.
13. Sinclair S, Hammond D, Goodman S. Sociodemographic differences in the comprehension of nutritional labels on food products. J Nutr Educ Behav. 2013;45(6):767-772.
14. von dem Knesebeck O, Mnich E, Daubmann A, et al. Socioeconomic status and beliefs about depression, schizophrenia and eating disorders. Soc Psychiatry Psychiatr Epidemiol. 2013;48(5):775-782.
15. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
16. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer. 2000;36(4):453-471.
17. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291(20):2441-2447.
18. Kaplan MH, Feinstein AR. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis. 1974;27 (7-8):387-404.
19. Chen RC, Royce TJ, Extermann M, Reeve BB. Impact of age and comorbidity on treatment and outcomes in elderly cancer patients. Semin Radiat Oncol. 2012;22(4):265-271.
20. Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med. 2005;37(5):360-363.
21. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-174.
22. National Comprehensive Cancer Network. NCCN Guidelines for Patients: Prostate Cancer. Fort Washington, PA: National Comprehensive Cancer Network; 2013.
23. Klabunde CN, Reeve BB, Harlan LC, Davis WW, Potosky AL. Do patients consistently report comorbid conditions over time? results from the prostate cancer outcomes study. Med Care. 2005; 43(4):391-400.
24. Graff JN, Mori M, Li H, et al. Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study. J Urol. 2007;177 (4):1307-1312.
25. Hoffman RM, Barry MJ, Stanford JL, Hamilton AS, Hunt WC, Collins MM. Health outcomes in older men with localized prostate cancer: results from the Prostate Cancer Outcomes Study. Am J Med. 2006; 119(5):418-425.
26. Yancik R, Havlik RJ, Wesley MN, et al. Cancer and comorbidity in older patients: a descriptive profile. Ann Epidemiol. 1996;6(5):399-412.
27. Coebergh JW, Janssen-Heijnen ML, Post PN, Razenberg PP. Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993-1996. J Clin Epidemiol. 1999;52(12):1131-1136.
28. Fowles JB, Fowler EJ, Craft C. Validation of claims diagnoses and self-reported conditions compared with medical records for selected chronic diseases. J Ambul Care Manage. 1998;21(1):24-34.
29. Skinner KM, Miller DR, Lincoln E, Lee A, Kazis LE. Concordance between respondent self-reports and medical records for chronic conditions: experience from the Veterans Health Study. J Ambul Care Manage. 2005;28(2):102-110.
30. Tisnado DM, Adams JL, Liu H, et al. What is the concordance between the medical record and patient self-report as data sources for ambulatory care? Med Care. 2006;44(2):132-140.
31. Basch E, Iasonos A, McDonough T, et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006;7 (11):903-909.
32. Basch E, Jia X, Heller G, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009;101(23):1624-1632.
33. Janse AJ, Gemke RJ, Uiterwaal CS, van der Tweel I, Kimpen JL, Sinnema G. Quality of life: patients and doctors don’t always agree: a meta-analysis. J Clin Epidemiol. 2004;57(7):653-661.
34. Martin NE, Massey L, Stowell C, et al. Defining a standard set of patient-centered outcomes for men with localized prostate cancer. Eur Urol. 2015;67 (3):460-467.